EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

DSCR1 deficiency ameliorates the Aβ pathology of Alzheimer’s disease by enhancing microglial activity

Chiyeol Choi, Hyerin Kim, Jiyoung Oh, Chanho Park, Min Kim, Chu-Sook Kim, Jiyoung Park iD

Life Science Alliance · 2023-02 · 6 (2) · e202201556

DOI: 10.26508/lsa.202201556 ↗

At a glance

Journal article in Life Science Alliance, published online on 2022-11-30. Written by Chiyeol Choi and 6 co-authors. Institution: Department of Biological Sciences, College of Information and Bioengineering, Ulsan National Institute of Science and Technology, Ulsan, Republic of …. Major MEDLINE topics: Alzheimer Disease, Down Syndrome. Cited 4 times so far (Crossref); 55 references. The full text is freely available (open access, CC BY 4.0). Funded by: Korea Health Industry Development Institute, National Research Foundation.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Microglial phagocytosis and clearance are important for the removal of amyloid-β (Aβ) plaques in Alzheimer’s disease (AD). Chronic exposure of microglia to Aβ plaques leads to microglial metabolic dysfunction, and dysregulation of microglia can accelerate the deposition of Aβ plaques and cause learning and memory impairment. Thus, regulating microglial Aβ clearance is crucial for the development of therapeutics for AD-related dementia. Here, Down syndrome critical region 1 (DSCR1) deficiency ameliorated Aβ plaque deposition in the 5xFAD mouse model of AD by altering microglial activity; however, the Aβ synthesis pathway was not affected. DSCR1 deficiency improved spatial learning and memory impairment in 5xFAD mice. Furthermore, DSCR1-deficient microglia exhibited accelerated lysosomal degradation of Aβ after phagocytosis, and BV2 cells with stable knockdown of DSCR1 demonstrated enhanced lysosomal activity. RNA-sequencing analysis showed that the transcriptional signatures associated with responses to IFN-γ were significantly up-regulated in DSCR1-knockdown BV2 cells treated with Aβ. Our data strongly suggest that DSCR1 is a critical mediator of microglial degradation of amyloid plaques and a new potential microglial therapeutic target in AD.

Subjects

MeSH terms (MEDLINE)

Alzheimer DiseaseDown SyndromeAnimalsMiceMicrogliaAmyloid beta-PeptidesPlaque, AmyloidCalcium-Binding ProteinsMuscle Proteins

Substances

Amyloid beta-PeptidesDSCR1 protein, mouseCalcium-Binding ProteinsMuscle Proteins

Authors and institutions

  • Department of Biological Sciences, College of Information and Bioengineering, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea.
  • Department of Biological Sciences, College of Information and Bioengineering, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea jpark@unist.ac.kr.

ORCID profiles: Jiyoung Park

Funding

  • Korea Health Industry Development Institute
  • National Research Foundation

Cite

APA

Choi, C., Kim, H., Oh, J., Park, C., Kim, M., Kim, C. S., & Park, J. (2023). DSCR1 deficiency ameliorates the Aβ pathology of Alzheimer’s disease by enhancing microglial activity. Life Science Alliance, 6(2), e202201556. https://doi.org/10.26508/lsa.202201556

Vancouver

Choi C, Kim H, Oh J, Park C, Kim M, Kim CS, et al. DSCR1 deficiency ameliorates the Aβ pathology of Alzheimer’s disease by enhancing microglial activity. Life Science Alliance. 2023;6(2):e202201556. doi:10.26508/lsa.202201556

BibTeX
@article{Choi2023,
  author = {Choi, Chiyeol and Kim, Hyerin and Oh, Jiyoung and Park, Chanho and Kim, Min and Kim, Chu-Sook and Park, Jiyoung},
  title = {DSCR1 deficiency ameliorates the Aβ pathology of Alzheimer’s disease by enhancing microglial activity},
  journal = {Life Science Alliance},
  year = {2023},
  volume = {6},
  number = {2},
  pages = {e202201556},
  doi = {10.26508/lsa.202201556}
}
Start for free →